Why Travere Therapeutics’ Stocks Did Not Fall During This Tuesday’s Bad Market

The Bear Market
The volatility in the Bear stock market continues to plunge the values of biotech stocks. The Bear market is sucking investors’ capitals who bet on firms with future growth potential based on early, mid term and late clinical trial results.     

Travere Therapeutics Good News

On February 17, 2023, before the long weekend that ended on Tuesday, Travere Therapeutics (TVTX) announced . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.